The anticancer ruthenium complex KP1019 induces DNA damage, leading to cell cycle delay and cell death in Saccharomyces cerevisiae

Molecular Pharmacology

Volumn 83, Issue 1, 2013, Pages 225-234

  Stevens, Shannon K ^a   Strehle, Amy P ^a   Miller, Rebecca L ^b   Gammons, Sarah H ^a   Hoffman, Kyle J ^a   McCarty, John T ^a   Miller, Mary E ^b   Stultz, Laura K ^a   Hanson, Pamela K ^a  

^a BIRMINGHAM SOUTHERN COLLEGE   (United States)

^b RHODES COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); RUTHENIUM COMPLEX; TRANS[TETRACHLOROBIS(1H INDAZOLE)RUTHENATE]; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOSTASIS; CYTOTOXICITY; DNA ADDUCT; DNA DAMAGE; DNA REPAIR; DRUG SENSITIVITY; DRUG TOLERANCE; EXCISION REPAIR; GAIN OF FUNCTION MUTATION; GENE; GENOTOXICITY; HYPERSENSITIVITY; NONHUMAN; PDR1 GENE; PRIORITY JOURNAL; SACCHAROMYCES CEREVISIAE; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DEATH; DNA DAMAGE; DNA HELICASES; DNA REPAIR; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG RESISTANCE, FUNGAL; INDAZOLES; ORGANOMETALLIC COMPOUNDS; SACCHAROMYCES CEREVISIAE; SACCHAROMYCES CEREVISIAE PROTEINS; TOPOISOMERASE II INHIBITORS; TRANSCRIPTION FACTOR TFIIH; TRANSCRIPTION FACTORS;

EID: 84871576245     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.079657     Document Type: Article

References (51)

1. Allardyce CS and Dyson PJ (2001) Ruthenium in medicine: current clinical uses and future prospects. Platin Met Rev 45:62-69. (Pubitemid 32535878)
2. Balzi E and Goffeau A (1995) Yeast multidrug resistance: the PDR network. J Bioenerg Biomembr 27:71-76.
3. Bauer BE, Wolfger H, and Kuchler K (1999) Inventory and function of yeast ABC proteins: about sex, stress, pleiotropic drug and heavy metal resistance. Biochim Biophys Acta 1461:217-236.
4. Beljanski V, Marzilli LG, and Doetsch PW (2004) DNA damage-processing pathways involved in the eukaryotic cellular response to anticancer DNA cross-linking drugs. Mol Pharmacol 65:1496-1506. (Pubitemid 38668307)
5. Berger MR, Garzon FT, Keppler BK, and Schmähl D (1989) Efficacy of new ruthenium complexes against chemically induced autochthonous colorectal carcinoma in rats. Anticancer Res 9:761-765. (Pubitemid 19194313)
6. Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, and Peters GJ (1996) Synergistic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 2:521-530. (Pubitemid 26099172)
7. Cardenas ME, Cruz MC, Del Poeta M, Chung N, Perfect JR, and Heitman J (1999) Antifungal activities of antineoplastic agents: Saccharomyces cerevisiae as a model system to study drug action. Clin Microbiol Rev 12:583-611. (Pubitemid 29484748)
8. Clarke MJ, Zhu F, and Frasca DR (1999) Non-platinum chemotherapeutic metallopharmaceuticals. Chem Rev 99:2511-2534.
9. Decottignies A, Grant AM, Nichols JW, de Wet H, McIntosh DB, and Goffeau A (1998) ATPase and multidrug transport activities of the overexpressed yeast ABC protein Yor1p. J Biol Chem 273:12612-12622. (Pubitemid 28240639)
10. Frühauf S and Zeller WJ (1991) New platinum, titanium, and ruthenium complexes with different patterns of DNA damage in rat ovarian tumor cells. Cancer Res 51:2943-2948.
11. Gietz RD and Woods RA (2002) Transformation of yeast by lithium acetate/single-stranded carrier DNA/polyethylene glycol method. Methods Enzymol 350:87-96. (Pubitemid 34619485)
12. Guarente L (1983) Yeast promoters and lacZ fusions designed to study expression of cloned genes in yeast. Methods Enzymol 101:181-191.
13. Guittet O, Håkansson P, Voevodskaya N, Fridd S, Gräslund A, Arakawa H, Nakamura Y, and Thelander L (2001) Mammalian p53R2 protein forms an active ribonucleotide reductase in vitro with the R1 protein, which is expressed both in resting cells in response to DNA damage and in proliferating cells. J Biol Chem 276:40647-40651.
14. Hartinger CG, Jakupec MA, Zorbas-Seifried S, Groessl M, Egger A, Berger W, Zorbas H, Dyson PJ, and Keppler BK (2008) KP1019, a new redox-active anticancer agent - preclinical development and results of a clinical phase I study in tumor patients. Chem Biodivers 5:2140-2155.
15. Heffeter P, Pongratz M, and Steiner E et al. (2005) Intrinsic and acquired forms of resistance against the anticancer ruthenium compound KP1019 [indazolium trans[tetrachlorobis(1H-indazole)ruthenate (III)] (FFC14A). J Pharmacol Exp Ther 312:281-289. (Pubitemid 40096479)
16. Heffeter P, Böck K, and Atil B et al. (2010) Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339. J Biol Inorg Chem 15:737-748.
17. Hughes TR (2002) Yeast and drug discovery. Funct Integr Genomics 2:199-211.
18. Huh WK, Falvo JV, Gerke LC, Carroll AS, Howson RW, Weissman JS, and O'Shea EK (2003) Global analysis of protein localization in budding yeast. Nature 425:686-691. (Pubitemid 37314307)
19. Ishida S, Lee J, Thiele DJ, and Herskowitz I (2002) Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA 99:14298-14302. (Pubitemid 35257666)
20. Jia X, Zhu Y, and Xiao W (2002) A stable and sensitive genotoxic testing system based on DNA damage induced gene expression in Saccharomyces cerevisiae. Mutat Res 519:83-92. (Pubitemid 34874989)
21. Jinks-Robertson S and Petes TD (1993) Experimental determination of rates of concerted evolution. Methods Enzymol 224:631-646.
22. Kapitza S, Jakupec MA, Uhl M, Keppler BK, and Marian B (2005) The heterocyclic ruthenium(III) complex KP1019 (FFC14A) causes DNA damage and oxidative stress in colorectal tumor cells. Cancer Lett 226:115-121. (Pubitemid 41039079)
23. Kean LS, Grant AM, Angeletti C, Mahé Y, Kuchler K, Fuller RS, and Nichols JW (1997) Plasma membrane translocation of fluorescent-labeled phosphatidylethanolamine is controlled by transcription regulators, PDR1 and PDR3. J Cell Biol 138:255-270. (Pubitemid 27323529)
24. Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7:573-584.
25. Kratz F, Hartmann M, Keppler B, and Messori L (1994) The binding properties of two antitumor ruthenium(III) complexes to apotransferrin. J Biol Chem 269:2581-2588. (Pubitemid 24235753)
26. Lentz F, Drescher A, Lindauer A, Henke M, Hilger RA, Hartinger CG, Scheulen ME, Dittrich C, Keppler BK, and Jaehde U; Central European Society for Anticancer Drug Research-EWIV (2009) Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study. Anticancer Drugs 20:97-103.
27. + ATPase and cytosolic acidification in sensitivity to DNA-damaging agents such as cisplatin. Mol Pharmacol 71:416-425.
28. Lipponer KG, Vogel E, and Keppler BK (1996) Synthesis, characterization, and solution chemistry of trans-indazoliumtetrachlorobis(indazole)ruthenate(III) , a new anticancer ruthenium complex. IR, UV, NMR, HPLC investigations and antitumor activity. Crystal structures of trans-1-methyl- indazoliumtetrachlorobis-(1-methylindazole)ruthenate(III) and its hydrolysis product trans-monoaquatrichlorobis- (1-methylindazole)-ruthenate(III). Met Based Drugs 3:243-260.
29. Lisby M, Rothstein R, and Mortensen UH (2001) Rad52 forms DNA repair and recombination centers during S phase. Proc Natl Acad Sci USA 98:8276-8282. (Pubitemid 32678024)
30. Martin LP, Hamilton TC, and Schilder RJ (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14:1291-1295. (Pubitemid 351413906)
31. Moye-Rowley WS (2003) Transcriptional control of multidrug resistance in the yeast Saccharomyces. Prog Nucleic Acid Res Mol Biol 73:251-279.
32. Murakami T, Shibuya I, and Ise T et al. (2001) Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. Int J Cancer 93:869-874. (Pubitemid 32756757)
33. Nitiss JL, Liu YX, Harbury P, Jannatipour M, Wasserman R, and Wang JC (1992) Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res 52:4467-4472.
34. Nyberg KA, Michelson RJ, Putnam CW, and Weinert TA (2002) Toward maintaining the genome: DNA damage and replication checkpoints. Annu Rev Genet 36:617-656. (Pubitemid 36109200)
35. Paumi CM, Chuk M, Snider J, Stagljar I, and Michaelis S (2009) ABC transporters in Saccharomyces cerevisiae and their interactors: new technology advances the biology of the ABCC (MRP) subfamily. Microbiol Mol Biol Rev 73:577-593.
36. Pongratz M, Schluga P, Jakupec M, Arion V, Hartinger C, Allmaier G, and Keppler B (2004) Transferrin binding and transferrin-mediated cellular uptake of the ruthenium coordination compound KP1019, studied by means of AAS, ESI-MS and CD spectroscopy. J Anal At Spectrom 19:46-51.
37. Rebillard A, Lagadic-Gossmann D, and Dimanche-Boitrel MT (2008) Cisplatin cytotoxicity: DNA and plasma membrane targets. Curr Med Chem 15:2656-2663.
38. Rogers B, Decottignies A, Kolaczkowski M, Carvajal E, Balzi E, and Goffeau A (2001) The pleitropic drug ABC transporters from Saccharomyces cerevisiae. J Mol Microbiol Biotechnol 3:207-214. (Pubitemid 32257905)
39. Sherman F, Fink GR, and Hicks JB (1986) Methods in Yeast Genetics, Cold Spring Harbor Laboratory Press, New York.
40. Sipos G and Kuchler K (2006) Fungal ATP-binding cassette (ABC) transporters in drug resistance & detoxification. Curr Drug Targets 7:471-481. (Pubitemid 43744838)
41. Skotheim JM, Di Talia S, Siggia ED, and Cross FR (2008) Positive feedback of G1 cyclins ensures coherent cell cycle entry. Nature 454:291-296. (Pubitemid 352009994)
42. Slupphaug G, Kavli B, and Krokan HE (2003) The interacting pathways for prevention and repair of oxidative DNA damage. Mutat Res 531:231-251. (Pubitemid 37456735)
43. Stepanov A, Nitiss KC, Neale G, and Nitiss JL (2008) Enhancing drug accumulation in Saccharomyces cerevisiae by repression of pleiotropic drug resistance genes with chimeric transcription repressors. Mol Pharmacol 74:423-431.
44. Symington LS (2002) Role of RAD52 epistasis group genes in homologous recombination and double-strand break repair. Microbiol Mol Biol Rev 66:630-670.
45. Vashisht Gopal YN and Kondapi AK (2001) Topoisomerase II poisoning by indazole and imidazole complexes of ruthenium. J Biosci 26:271-276. (Pubitemid 32601721)
46. Watt PM and Hickson ID (1994) Structure and function of type II DNA topoisomerases. Biochem J 303:681-695. (Pubitemid 24325996)
47. Whelan WL, Gocke E, and Manney TR (1979) The CAN1 locus of Saccharomyces cerevisiae: fine-structure analysis and forward mutation rates. Genetics 91:35-51. (Pubitemid 9105420)
48. Winzeler EA, Shoemaker DD, and Astromoff A et al. (1999) Functional characterization of the S. cerevisiae genome by gene deletion and parallel analysis. Science 285:901-906. (Pubitemid 29381993)
49. Yang SS, Yeh E, Salmon ED, and Bloom K (1997) Identification of a mid-anaphase checkpoint in budding yeast. J Cell Biol 136:345-354. (Pubitemid 27063084)
50. Zhang CX and Lippard SJ (2003) New metal complexes as potential therapeutics. Curr Opin Chem Biol 7:481-489. (Pubitemid 36980839)
51. Zhou Z and Elledge SJ (1992) Isolation of crt mutants constitutive for transcription of the DNA damage inducible gene RNR3 in Saccharomyces cerevisiae. Genetics 131:851-866.